920509-27-9 Usage
General Description
Benzenamine, 3,5-dichloro-4-[[6-chloro-5-(1-methylethyl)-3-pyridazinyl]oxy]- is a chemical compound with a complex structure. It contains a benzene ring with two attached chlorine atoms and a pyridazinyl group linked to an oxygen atom. Additionally, there is a chloro substituent and an isopropyl group attached to the pyridazinyl moiety. Benzenamine,
3,5-dichloro-4-[[6-chloro-5-(1-methylethyl)-3-pyridazinyl]oxy]- may have potential applications in various fields, including pharmaceuticals and agrochemicals, due to its unique structure and properties. Further research and studies are needed to explore its potential uses and effects.
Check Digit Verification of cas no
The CAS Registry Mumber 920509-27-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,0,5,0 and 9 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 920509-27:
(8*9)+(7*2)+(6*0)+(5*5)+(4*0)+(3*9)+(2*2)+(1*7)=149
149 % 10 = 9
So 920509-27-9 is a valid CAS Registry Number.
920509-27-9Relevant articles and documents
Substituted pyridazinone compound and application thereof
-
Paragraph 0086-0088; 0091-0092, (2021/04/14)
The invention provides a substituted pyridazinone compound and application thereof. The substituted pyridazinone compound is a compound shown in a general formula I, or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a poly
THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
-
Paragraph 0366; 0368, (2020/05/02)
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
-
Paragraph 0305, (2020/03/09)
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
